K-Cab Dosage/Direction for Use

Posology: In adult: Treatment of Erosive Gastroesophageal Reflux Disease: 50 mg once daily for 4 weeks. For patients who do not heal or have persistent symptoms after 4 weeks, an additional 4-week treatment may be considered.
Treatment of Non-Erosive Gastroesophageal Reflux Disease: 50 mg once daily for 4 weeks.
Treatment of Gastric Ulcer: 50 mg once daily for 8 weeks.
Eradication of H. pylori concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis: Patients with H. pylori infection should be treated with eradication therapy. Tegoprazan 50 mg, clarithromycin 500 mg, and amoxicillin 1 g are orally administered twice daily for 7 days.
K-CAB Tablet 50 mg can be taken without regard to food.
Hepatic impairment: There is no data on patients with hepatic impairment.
Renal impairment: There is no data on patients with renal impairment.
Elderly people: In general, it should be administered to the elderly patients with caution, keeping in mind the greater frequency of decreased physiological functions, such as liver or kidney.
Pediatric population: Clinical safety and efficacy of K-CAB Tablet 50 mg in pediatric and adolescent patients have not been established.